CTNI-16. Monogerm, a novel proof-of-principle Bayesian phase II trial design of carboplatin or vinblastine monotherapy induction prior to radiotherapy for intracranial germinoma

Kirton, L., Apps, J., Lawson, A. et al. (16 more authors) (2024) CTNI-16. Monogerm, a novel proof-of-principle Bayesian phase II trial design of carboplatin or vinblastine monotherapy induction prior to radiotherapy for intracranial germinoma. In: 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, 21-24 Nov 2024, Houston, Texas.

Metadata

Item Type: Conference or Workshop Item
Authors/Creators:
  • Kirton, L.
  • Apps, J.
  • Lawson, A.
  • Arvanitis, T.
  • Mitra, D.
  • Gagan, R.
  • Patel, H.
  • Peet, A.
  • Fern, L.
  • Williams, E.
  • Coleman, N.
  • Ajithkumar, T.
  • Bison, B.
  • Veal, G.
  • Stark, D. ORCID logo https://orcid.org/0000-0002-6172-733X
  • Morana, G.
  • Nicholson, J.
  • Billingham, L.
  • Murray, M.
Dates:
  • Published: 11 November 2024
  • Published (online): 11 November 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology
Funding Information:
Funder
Grant number
NIHR National Inst Health Research
TYA CAN COHORT STY G569
Depositing User: Symplectic Publications
Date Deposited: 14 Jan 2025 11:13
Last Modified: 14 Jan 2025 11:14
Published Version: https://academic.oup.com/neuro-oncology/article/26...
Status: Published
Publisher: Oxford University Press (OUP)
Identification Number: 10.1093/neuonc/noae165.0383
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics